Research ArticleArticle
Establishing a Core Domain Set to Measure Rheumatoid Arthritis Flares: Report of the OMERACT 11 RA Flare Workshop
Vivian P. Bykerk, Elisabeth Lie, Susan J. Bartlett, Rieke Alten, Annelies Boonen, Robin Christensen, Daniel E. Furst, Sarah Hewlett, Amye L. Leong, Anne Lyddiatt, Lyn March, James E. May, Pam Montie, Ana-Maria Orbai, Christoph Pohl, Marieke Scholte Voshaar, Thasia Woodworth, Clifton O. Bingham III and Ernest H. Choy
The Journal of Rheumatology March 2014, jrheum.131252; DOI: https://doi.org/10.3899/jrheum.131252
Vivian P. Bykerk
From the Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Johns Hopkins University, Baltimore, Maryland, USA; McGill University, Montreal, Quebec, Canada; Schlosspark Klinik, Charité University Medicine, Berlin, Germany; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht, The Netherlands; Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark; David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA; University of the West of England, Bristol, UK; Healthy Motivation, Bone and Joint Decade, Santa Barbara, California, USA; Musculoskeletal Group, Cochrane Collaboration; University of Sydney Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; National Fathers’ Network, Seattle, Washington, USA; Arthritis Research Center, Vancouver, British Columbia, Canada; Tools2use.eu, Bussum, The Netherlands; and the Department of Rheumatology, Cardiff University, Cardiff, UK. The OMERACT RA Flare working group received financial and/or logistical and data support from Novartis, Amgen Canada, UCB, and Pfizer. V. Bykerk, principal investigator of the CATCH cohort, has received research grants from, and/or served as a member of advisory boards for, Abbott Laboratories, Amgen, Antares, Astellas, Boehringer Ingelheim, Bristol Meyers Squibb, Janssen Biotech, Pfizer, Merck, Roche, Genentech, and UCB. She is funded by the Cedar Hill Foundation. E. Lie has served on advisory boards for and/or received consultancy/speaker honoraria from Pfizer, Roche, Bristol-Myers Squibb, and Abbvie. R. Alten has received research grants and served as a member of advisory boards and speaker bureaus of Abbott Laboratories, Bristol-Myers Squibb, Chugai Pharma, Horizon, GSK, MSD, Novartis, Pfizer, Roche, Schering Plough, and UCB. C.O. Bingham III has received research grants and/or served as a consultant to Abbott, Amgen, BMS, Celgene, Genentech/Roche, Janssen/Johnson and Johnson/Centocor, Pfizer, and UCB. Work reported in this publication has been supported by the Ira Fine Discovery Fund, the Sibley Hospital Memorial Fund, and the Johns Hopkins Arthritis Center Discovery Fund. S. Bartlett has received consultancy/speaker honoraria from Amgen, Pfizer, Roche, UCB, Biogen, and Abbott; A. Boonen received educational grants from Abbott, MSD, and Amgen and speakers’ honoraria from UCB, Abbott, and Pfizer. R. Christensen has received grant support and/or provided expert advice and/or presentations for Abbott/AbbVie, Axellus, Bayer HealthCare Pharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Cambridge Weight Plan, Ipsen, Laboratoires Expanscience, MSD, Mundipharma, Norpharma, Pfizer, Roche, and Wyeth. L. March is Chair of the Australian Biologics Registry, which receives unrestricted educational grants from Abbott Australasia, Pfizer Australia, Bristol Myers Squibb Australia, and Janssen-Cilag Australasia. A-M. Orbai is supported by the US National Institutes of Health T32-AR48522 and was supported to attend OMERACT 11 by the American College of Rheumatology and the Johns Hopkins Arthritis Center Discovery Fund. D. Furst has received research grants, and served as member of advisory boards and consultancy from Abbott, Actelion, Amgen, BMS, Biogen Idec, Janssen, Gilead, GSK, Novartis, Pfizer, Roche/Genentech, and UCB. He has also a member of the speaker bureau of Abbott, Actelion, and UCB. T. Woodworth is a former employee of Pfizer, Novartis, and Roche/Genentech. E. Choy has received research grants and served as member of advisory boards and speaker bureaus of Abbott Laboratories, Allergan, AstraZeneca, Boehringer Ingelheim, Chelsea Therapeutics, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Ferring Pharmaceutical, GSK, Jazz Pharmaceuticals, MedImmune, Merrimack Pharmaceutical, MSD, Novartis, Pfizer, Pierre Fabre Medicament, Roche, Schering Plough, Synovate, and UCB. V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery; E. Lie, MD, Department of Rheumatology, Diakonhjemmet Hospital; S.J. Bartlett, PhD, Johns Hopkins University, McGill University; R. Alten, MD, Schlosspark Klinik, Charité University Medicine; A. Boonen, MD, PhD, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute; R. Christensen, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital; D.E. Furst, MD, David Geffen School of Medicine, University of California at Los Angeles; S. Hewlett, PhD, RN, University of the West of England, Bristol, UK; A.L. Leong, Healthy Motivation, Bone and Joint Decade; A. Lyddiatt, Musculoskeletal Group, Cochrane Collaboration; L. March, MD, PhD, University of Sydney Department of Rheumatology, Royal North Shore Hospital; J.E. May, National Fathers’ Network; P. Montie, Arthritis Research Center; A-M. Orbai, MD, Johns Hopkins University; C. Pohl, MD, Schlosspark Klinik; M. Scholte Voshaar, Tools2use.eu; T. Woodworth, David Geffen School of Medicine, University of California at Los Angeles; C.O. Bingham III, MD, Johns Hopkins University; and E.H. Choy, MD, FRCP, Department of Rheumatology, Cardiff University. Address correspondence to Dr. Bykerk, Department of Rheumatology, Hospital for Special Surgery, 535 East 70th St., New York, New York 07030, USA. E-mail: bykerkv@hss.edu
Elisabeth Lie
From the Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Johns Hopkins University, Baltimore, Maryland, USA; McGill University, Montreal, Quebec, Canada; Schlosspark Klinik, Charité University Medicine, Berlin, Germany; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht, The Netherlands; Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark; David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA; University of the West of England, Bristol, UK; Healthy Motivation, Bone and Joint Decade, Santa Barbara, California, USA; Musculoskeletal Group, Cochrane Collaboration; University of Sydney Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; National Fathers’ Network, Seattle, Washington, USA; Arthritis Research Center, Vancouver, British Columbia, Canada; Tools2use.eu, Bussum, The Netherlands; and the Department of Rheumatology, Cardiff University, Cardiff, UK. The OMERACT RA Flare working group received financial and/or logistical and data support from Novartis, Amgen Canada, UCB, and Pfizer. V. Bykerk, principal investigator of the CATCH cohort, has received research grants from, and/or served as a member of advisory boards for, Abbott Laboratories, Amgen, Antares, Astellas, Boehringer Ingelheim, Bristol Meyers Squibb, Janssen Biotech, Pfizer, Merck, Roche, Genentech, and UCB. She is funded by the Cedar Hill Foundation. E. Lie has served on advisory boards for and/or received consultancy/speaker honoraria from Pfizer, Roche, Bristol-Myers Squibb, and Abbvie. R. Alten has received research grants and served as a member of advisory boards and speaker bureaus of Abbott Laboratories, Bristol-Myers Squibb, Chugai Pharma, Horizon, GSK, MSD, Novartis, Pfizer, Roche, Schering Plough, and UCB. C.O. Bingham III has received research grants and/or served as a consultant to Abbott, Amgen, BMS, Celgene, Genentech/Roche, Janssen/Johnson and Johnson/Centocor, Pfizer, and UCB. Work reported in this publication has been supported by the Ira Fine Discovery Fund, the Sibley Hospital Memorial Fund, and the Johns Hopkins Arthritis Center Discovery Fund. S. Bartlett has received consultancy/speaker honoraria from Amgen, Pfizer, Roche, UCB, Biogen, and Abbott; A. Boonen received educational grants from Abbott, MSD, and Amgen and speakers’ honoraria from UCB, Abbott, and Pfizer. R. Christensen has received grant support and/or provided expert advice and/or presentations for Abbott/AbbVie, Axellus, Bayer HealthCare Pharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Cambridge Weight Plan, Ipsen, Laboratoires Expanscience, MSD, Mundipharma, Norpharma, Pfizer, Roche, and Wyeth. L. March is Chair of the Australian Biologics Registry, which receives unrestricted educational grants from Abbott Australasia, Pfizer Australia, Bristol Myers Squibb Australia, and Janssen-Cilag Australasia. A-M. Orbai is supported by the US National Institutes of Health T32-AR48522 and was supported to attend OMERACT 11 by the American College of Rheumatology and the Johns Hopkins Arthritis Center Discovery Fund. D. Furst has received research grants, and served as member of advisory boards and consultancy from Abbott, Actelion, Amgen, BMS, Biogen Idec, Janssen, Gilead, GSK, Novartis, Pfizer, Roche/Genentech, and UCB. He has also a member of the speaker bureau of Abbott, Actelion, and UCB. T. Woodworth is a former employee of Pfizer, Novartis, and Roche/Genentech. E. Choy has received research grants and served as member of advisory boards and speaker bureaus of Abbott Laboratories, Allergan, AstraZeneca, Boehringer Ingelheim, Chelsea Therapeutics, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Ferring Pharmaceutical, GSK, Jazz Pharmaceuticals, MedImmune, Merrimack Pharmaceutical, MSD, Novartis, Pfizer, Pierre Fabre Medicament, Roche, Schering Plough, Synovate, and UCB. V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery; E. Lie, MD, Department of Rheumatology, Diakonhjemmet Hospital; S.J. Bartlett, PhD, Johns Hopkins University, McGill University; R. Alten, MD, Schlosspark Klinik, Charité University Medicine; A. Boonen, MD, PhD, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute; R. Christensen, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital; D.E. Furst, MD, David Geffen School of Medicine, University of California at Los Angeles; S. Hewlett, PhD, RN, University of the West of England, Bristol, UK; A.L. Leong, Healthy Motivation, Bone and Joint Decade; A. Lyddiatt, Musculoskeletal Group, Cochrane Collaboration; L. March, MD, PhD, University of Sydney Department of Rheumatology, Royal North Shore Hospital; J.E. May, National Fathers’ Network; P. Montie, Arthritis Research Center; A-M. Orbai, MD, Johns Hopkins University; C. Pohl, MD, Schlosspark Klinik; M. Scholte Voshaar, Tools2use.eu; T. Woodworth, David Geffen School of Medicine, University of California at Los Angeles; C.O. Bingham III, MD, Johns Hopkins University; and E.H. Choy, MD, FRCP, Department of Rheumatology, Cardiff University. Address correspondence to Dr. Bykerk, Department of Rheumatology, Hospital for Special Surgery, 535 East 70th St., New York, New York 07030, USA. E-mail: bykerkv@hss.edu
Susan J. Bartlett
From the Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Johns Hopkins University, Baltimore, Maryland, USA; McGill University, Montreal, Quebec, Canada; Schlosspark Klinik, Charité University Medicine, Berlin, Germany; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht, The Netherlands; Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark; David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA; University of the West of England, Bristol, UK; Healthy Motivation, Bone and Joint Decade, Santa Barbara, California, USA; Musculoskeletal Group, Cochrane Collaboration; University of Sydney Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; National Fathers’ Network, Seattle, Washington, USA; Arthritis Research Center, Vancouver, British Columbia, Canada; Tools2use.eu, Bussum, The Netherlands; and the Department of Rheumatology, Cardiff University, Cardiff, UK. The OMERACT RA Flare working group received financial and/or logistical and data support from Novartis, Amgen Canada, UCB, and Pfizer. V. Bykerk, principal investigator of the CATCH cohort, has received research grants from, and/or served as a member of advisory boards for, Abbott Laboratories, Amgen, Antares, Astellas, Boehringer Ingelheim, Bristol Meyers Squibb, Janssen Biotech, Pfizer, Merck, Roche, Genentech, and UCB. She is funded by the Cedar Hill Foundation. E. Lie has served on advisory boards for and/or received consultancy/speaker honoraria from Pfizer, Roche, Bristol-Myers Squibb, and Abbvie. R. Alten has received research grants and served as a member of advisory boards and speaker bureaus of Abbott Laboratories, Bristol-Myers Squibb, Chugai Pharma, Horizon, GSK, MSD, Novartis, Pfizer, Roche, Schering Plough, and UCB. C.O. Bingham III has received research grants and/or served as a consultant to Abbott, Amgen, BMS, Celgene, Genentech/Roche, Janssen/Johnson and Johnson/Centocor, Pfizer, and UCB. Work reported in this publication has been supported by the Ira Fine Discovery Fund, the Sibley Hospital Memorial Fund, and the Johns Hopkins Arthritis Center Discovery Fund. S. Bartlett has received consultancy/speaker honoraria from Amgen, Pfizer, Roche, UCB, Biogen, and Abbott; A. Boonen received educational grants from Abbott, MSD, and Amgen and speakers’ honoraria from UCB, Abbott, and Pfizer. R. Christensen has received grant support and/or provided expert advice and/or presentations for Abbott/AbbVie, Axellus, Bayer HealthCare Pharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Cambridge Weight Plan, Ipsen, Laboratoires Expanscience, MSD, Mundipharma, Norpharma, Pfizer, Roche, and Wyeth. L. March is Chair of the Australian Biologics Registry, which receives unrestricted educational grants from Abbott Australasia, Pfizer Australia, Bristol Myers Squibb Australia, and Janssen-Cilag Australasia. A-M. Orbai is supported by the US National Institutes of Health T32-AR48522 and was supported to attend OMERACT 11 by the American College of Rheumatology and the Johns Hopkins Arthritis Center Discovery Fund. D. Furst has received research grants, and served as member of advisory boards and consultancy from Abbott, Actelion, Amgen, BMS, Biogen Idec, Janssen, Gilead, GSK, Novartis, Pfizer, Roche/Genentech, and UCB. He has also a member of the speaker bureau of Abbott, Actelion, and UCB. T. Woodworth is a former employee of Pfizer, Novartis, and Roche/Genentech. E. Choy has received research grants and served as member of advisory boards and speaker bureaus of Abbott Laboratories, Allergan, AstraZeneca, Boehringer Ingelheim, Chelsea Therapeutics, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Ferring Pharmaceutical, GSK, Jazz Pharmaceuticals, MedImmune, Merrimack Pharmaceutical, MSD, Novartis, Pfizer, Pierre Fabre Medicament, Roche, Schering Plough, Synovate, and UCB. V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery; E. Lie, MD, Department of Rheumatology, Diakonhjemmet Hospital; S.J. Bartlett, PhD, Johns Hopkins University, McGill University; R. Alten, MD, Schlosspark Klinik, Charité University Medicine; A. Boonen, MD, PhD, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute; R. Christensen, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital; D.E. Furst, MD, David Geffen School of Medicine, University of California at Los Angeles; S. Hewlett, PhD, RN, University of the West of England, Bristol, UK; A.L. Leong, Healthy Motivation, Bone and Joint Decade; A. Lyddiatt, Musculoskeletal Group, Cochrane Collaboration; L. March, MD, PhD, University of Sydney Department of Rheumatology, Royal North Shore Hospital; J.E. May, National Fathers’ Network; P. Montie, Arthritis Research Center; A-M. Orbai, MD, Johns Hopkins University; C. Pohl, MD, Schlosspark Klinik; M. Scholte Voshaar, Tools2use.eu; T. Woodworth, David Geffen School of Medicine, University of California at Los Angeles; C.O. Bingham III, MD, Johns Hopkins University; and E.H. Choy, MD, FRCP, Department of Rheumatology, Cardiff University. Address correspondence to Dr. Bykerk, Department of Rheumatology, Hospital for Special Surgery, 535 East 70th St., New York, New York 07030, USA. E-mail: bykerkv@hss.edu
Rieke Alten
From the Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Johns Hopkins University, Baltimore, Maryland, USA; McGill University, Montreal, Quebec, Canada; Schlosspark Klinik, Charité University Medicine, Berlin, Germany; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht, The Netherlands; Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark; David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA; University of the West of England, Bristol, UK; Healthy Motivation, Bone and Joint Decade, Santa Barbara, California, USA; Musculoskeletal Group, Cochrane Collaboration; University of Sydney Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; National Fathers’ Network, Seattle, Washington, USA; Arthritis Research Center, Vancouver, British Columbia, Canada; Tools2use.eu, Bussum, The Netherlands; and the Department of Rheumatology, Cardiff University, Cardiff, UK. The OMERACT RA Flare working group received financial and/or logistical and data support from Novartis, Amgen Canada, UCB, and Pfizer. V. Bykerk, principal investigator of the CATCH cohort, has received research grants from, and/or served as a member of advisory boards for, Abbott Laboratories, Amgen, Antares, Astellas, Boehringer Ingelheim, Bristol Meyers Squibb, Janssen Biotech, Pfizer, Merck, Roche, Genentech, and UCB. She is funded by the Cedar Hill Foundation. E. Lie has served on advisory boards for and/or received consultancy/speaker honoraria from Pfizer, Roche, Bristol-Myers Squibb, and Abbvie. R. Alten has received research grants and served as a member of advisory boards and speaker bureaus of Abbott Laboratories, Bristol-Myers Squibb, Chugai Pharma, Horizon, GSK, MSD, Novartis, Pfizer, Roche, Schering Plough, and UCB. C.O. Bingham III has received research grants and/or served as a consultant to Abbott, Amgen, BMS, Celgene, Genentech/Roche, Janssen/Johnson and Johnson/Centocor, Pfizer, and UCB. Work reported in this publication has been supported by the Ira Fine Discovery Fund, the Sibley Hospital Memorial Fund, and the Johns Hopkins Arthritis Center Discovery Fund. S. Bartlett has received consultancy/speaker honoraria from Amgen, Pfizer, Roche, UCB, Biogen, and Abbott; A. Boonen received educational grants from Abbott, MSD, and Amgen and speakers’ honoraria from UCB, Abbott, and Pfizer. R. Christensen has received grant support and/or provided expert advice and/or presentations for Abbott/AbbVie, Axellus, Bayer HealthCare Pharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Cambridge Weight Plan, Ipsen, Laboratoires Expanscience, MSD, Mundipharma, Norpharma, Pfizer, Roche, and Wyeth. L. March is Chair of the Australian Biologics Registry, which receives unrestricted educational grants from Abbott Australasia, Pfizer Australia, Bristol Myers Squibb Australia, and Janssen-Cilag Australasia. A-M. Orbai is supported by the US National Institutes of Health T32-AR48522 and was supported to attend OMERACT 11 by the American College of Rheumatology and the Johns Hopkins Arthritis Center Discovery Fund. D. Furst has received research grants, and served as member of advisory boards and consultancy from Abbott, Actelion, Amgen, BMS, Biogen Idec, Janssen, Gilead, GSK, Novartis, Pfizer, Roche/Genentech, and UCB. He has also a member of the speaker bureau of Abbott, Actelion, and UCB. T. Woodworth is a former employee of Pfizer, Novartis, and Roche/Genentech. E. Choy has received research grants and served as member of advisory boards and speaker bureaus of Abbott Laboratories, Allergan, AstraZeneca, Boehringer Ingelheim, Chelsea Therapeutics, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Ferring Pharmaceutical, GSK, Jazz Pharmaceuticals, MedImmune, Merrimack Pharmaceutical, MSD, Novartis, Pfizer, Pierre Fabre Medicament, Roche, Schering Plough, Synovate, and UCB. V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery; E. Lie, MD, Department of Rheumatology, Diakonhjemmet Hospital; S.J. Bartlett, PhD, Johns Hopkins University, McGill University; R. Alten, MD, Schlosspark Klinik, Charité University Medicine; A. Boonen, MD, PhD, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute; R. Christensen, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital; D.E. Furst, MD, David Geffen School of Medicine, University of California at Los Angeles; S. Hewlett, PhD, RN, University of the West of England, Bristol, UK; A.L. Leong, Healthy Motivation, Bone and Joint Decade; A. Lyddiatt, Musculoskeletal Group, Cochrane Collaboration; L. March, MD, PhD, University of Sydney Department of Rheumatology, Royal North Shore Hospital; J.E. May, National Fathers’ Network; P. Montie, Arthritis Research Center; A-M. Orbai, MD, Johns Hopkins University; C. Pohl, MD, Schlosspark Klinik; M. Scholte Voshaar, Tools2use.eu; T. Woodworth, David Geffen School of Medicine, University of California at Los Angeles; C.O. Bingham III, MD, Johns Hopkins University; and E.H. Choy, MD, FRCP, Department of Rheumatology, Cardiff University. Address correspondence to Dr. Bykerk, Department of Rheumatology, Hospital for Special Surgery, 535 East 70th St., New York, New York 07030, USA. E-mail: bykerkv@hss.edu
Annelies Boonen
From the Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Johns Hopkins University, Baltimore, Maryland, USA; McGill University, Montreal, Quebec, Canada; Schlosspark Klinik, Charité University Medicine, Berlin, Germany; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht, The Netherlands; Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark; David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA; University of the West of England, Bristol, UK; Healthy Motivation, Bone and Joint Decade, Santa Barbara, California, USA; Musculoskeletal Group, Cochrane Collaboration; University of Sydney Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; National Fathers’ Network, Seattle, Washington, USA; Arthritis Research Center, Vancouver, British Columbia, Canada; Tools2use.eu, Bussum, The Netherlands; and the Department of Rheumatology, Cardiff University, Cardiff, UK. The OMERACT RA Flare working group received financial and/or logistical and data support from Novartis, Amgen Canada, UCB, and Pfizer. V. Bykerk, principal investigator of the CATCH cohort, has received research grants from, and/or served as a member of advisory boards for, Abbott Laboratories, Amgen, Antares, Astellas, Boehringer Ingelheim, Bristol Meyers Squibb, Janssen Biotech, Pfizer, Merck, Roche, Genentech, and UCB. She is funded by the Cedar Hill Foundation. E. Lie has served on advisory boards for and/or received consultancy/speaker honoraria from Pfizer, Roche, Bristol-Myers Squibb, and Abbvie. R. Alten has received research grants and served as a member of advisory boards and speaker bureaus of Abbott Laboratories, Bristol-Myers Squibb, Chugai Pharma, Horizon, GSK, MSD, Novartis, Pfizer, Roche, Schering Plough, and UCB. C.O. Bingham III has received research grants and/or served as a consultant to Abbott, Amgen, BMS, Celgene, Genentech/Roche, Janssen/Johnson and Johnson/Centocor, Pfizer, and UCB. Work reported in this publication has been supported by the Ira Fine Discovery Fund, the Sibley Hospital Memorial Fund, and the Johns Hopkins Arthritis Center Discovery Fund. S. Bartlett has received consultancy/speaker honoraria from Amgen, Pfizer, Roche, UCB, Biogen, and Abbott; A. Boonen received educational grants from Abbott, MSD, and Amgen and speakers’ honoraria from UCB, Abbott, and Pfizer. R. Christensen has received grant support and/or provided expert advice and/or presentations for Abbott/AbbVie, Axellus, Bayer HealthCare Pharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Cambridge Weight Plan, Ipsen, Laboratoires Expanscience, MSD, Mundipharma, Norpharma, Pfizer, Roche, and Wyeth. L. March is Chair of the Australian Biologics Registry, which receives unrestricted educational grants from Abbott Australasia, Pfizer Australia, Bristol Myers Squibb Australia, and Janssen-Cilag Australasia. A-M. Orbai is supported by the US National Institutes of Health T32-AR48522 and was supported to attend OMERACT 11 by the American College of Rheumatology and the Johns Hopkins Arthritis Center Discovery Fund. D. Furst has received research grants, and served as member of advisory boards and consultancy from Abbott, Actelion, Amgen, BMS, Biogen Idec, Janssen, Gilead, GSK, Novartis, Pfizer, Roche/Genentech, and UCB. He has also a member of the speaker bureau of Abbott, Actelion, and UCB. T. Woodworth is a former employee of Pfizer, Novartis, and Roche/Genentech. E. Choy has received research grants and served as member of advisory boards and speaker bureaus of Abbott Laboratories, Allergan, AstraZeneca, Boehringer Ingelheim, Chelsea Therapeutics, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Ferring Pharmaceutical, GSK, Jazz Pharmaceuticals, MedImmune, Merrimack Pharmaceutical, MSD, Novartis, Pfizer, Pierre Fabre Medicament, Roche, Schering Plough, Synovate, and UCB. V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery; E. Lie, MD, Department of Rheumatology, Diakonhjemmet Hospital; S.J. Bartlett, PhD, Johns Hopkins University, McGill University; R. Alten, MD, Schlosspark Klinik, Charité University Medicine; A. Boonen, MD, PhD, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute; R. Christensen, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital; D.E. Furst, MD, David Geffen School of Medicine, University of California at Los Angeles; S. Hewlett, PhD, RN, University of the West of England, Bristol, UK; A.L. Leong, Healthy Motivation, Bone and Joint Decade; A. Lyddiatt, Musculoskeletal Group, Cochrane Collaboration; L. March, MD, PhD, University of Sydney Department of Rheumatology, Royal North Shore Hospital; J.E. May, National Fathers’ Network; P. Montie, Arthritis Research Center; A-M. Orbai, MD, Johns Hopkins University; C. Pohl, MD, Schlosspark Klinik; M. Scholte Voshaar, Tools2use.eu; T. Woodworth, David Geffen School of Medicine, University of California at Los Angeles; C.O. Bingham III, MD, Johns Hopkins University; and E.H. Choy, MD, FRCP, Department of Rheumatology, Cardiff University. Address correspondence to Dr. Bykerk, Department of Rheumatology, Hospital for Special Surgery, 535 East 70th St., New York, New York 07030, USA. E-mail: bykerkv@hss.edu
Robin Christensen
From the Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Johns Hopkins University, Baltimore, Maryland, USA; McGill University, Montreal, Quebec, Canada; Schlosspark Klinik, Charité University Medicine, Berlin, Germany; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht, The Netherlands; Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark; David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA; University of the West of England, Bristol, UK; Healthy Motivation, Bone and Joint Decade, Santa Barbara, California, USA; Musculoskeletal Group, Cochrane Collaboration; University of Sydney Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; National Fathers’ Network, Seattle, Washington, USA; Arthritis Research Center, Vancouver, British Columbia, Canada; Tools2use.eu, Bussum, The Netherlands; and the Department of Rheumatology, Cardiff University, Cardiff, UK. The OMERACT RA Flare working group received financial and/or logistical and data support from Novartis, Amgen Canada, UCB, and Pfizer. V. Bykerk, principal investigator of the CATCH cohort, has received research grants from, and/or served as a member of advisory boards for, Abbott Laboratories, Amgen, Antares, Astellas, Boehringer Ingelheim, Bristol Meyers Squibb, Janssen Biotech, Pfizer, Merck, Roche, Genentech, and UCB. She is funded by the Cedar Hill Foundation. E. Lie has served on advisory boards for and/or received consultancy/speaker honoraria from Pfizer, Roche, Bristol-Myers Squibb, and Abbvie. R. Alten has received research grants and served as a member of advisory boards and speaker bureaus of Abbott Laboratories, Bristol-Myers Squibb, Chugai Pharma, Horizon, GSK, MSD, Novartis, Pfizer, Roche, Schering Plough, and UCB. C.O. Bingham III has received research grants and/or served as a consultant to Abbott, Amgen, BMS, Celgene, Genentech/Roche, Janssen/Johnson and Johnson/Centocor, Pfizer, and UCB. Work reported in this publication has been supported by the Ira Fine Discovery Fund, the Sibley Hospital Memorial Fund, and the Johns Hopkins Arthritis Center Discovery Fund. S. Bartlett has received consultancy/speaker honoraria from Amgen, Pfizer, Roche, UCB, Biogen, and Abbott; A. Boonen received educational grants from Abbott, MSD, and Amgen and speakers’ honoraria from UCB, Abbott, and Pfizer. R. Christensen has received grant support and/or provided expert advice and/or presentations for Abbott/AbbVie, Axellus, Bayer HealthCare Pharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Cambridge Weight Plan, Ipsen, Laboratoires Expanscience, MSD, Mundipharma, Norpharma, Pfizer, Roche, and Wyeth. L. March is Chair of the Australian Biologics Registry, which receives unrestricted educational grants from Abbott Australasia, Pfizer Australia, Bristol Myers Squibb Australia, and Janssen-Cilag Australasia. A-M. Orbai is supported by the US National Institutes of Health T32-AR48522 and was supported to attend OMERACT 11 by the American College of Rheumatology and the Johns Hopkins Arthritis Center Discovery Fund. D. Furst has received research grants, and served as member of advisory boards and consultancy from Abbott, Actelion, Amgen, BMS, Biogen Idec, Janssen, Gilead, GSK, Novartis, Pfizer, Roche/Genentech, and UCB. He has also a member of the speaker bureau of Abbott, Actelion, and UCB. T. Woodworth is a former employee of Pfizer, Novartis, and Roche/Genentech. E. Choy has received research grants and served as member of advisory boards and speaker bureaus of Abbott Laboratories, Allergan, AstraZeneca, Boehringer Ingelheim, Chelsea Therapeutics, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Ferring Pharmaceutical, GSK, Jazz Pharmaceuticals, MedImmune, Merrimack Pharmaceutical, MSD, Novartis, Pfizer, Pierre Fabre Medicament, Roche, Schering Plough, Synovate, and UCB. V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery; E. Lie, MD, Department of Rheumatology, Diakonhjemmet Hospital; S.J. Bartlett, PhD, Johns Hopkins University, McGill University; R. Alten, MD, Schlosspark Klinik, Charité University Medicine; A. Boonen, MD, PhD, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute; R. Christensen, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital; D.E. Furst, MD, David Geffen School of Medicine, University of California at Los Angeles; S. Hewlett, PhD, RN, University of the West of England, Bristol, UK; A.L. Leong, Healthy Motivation, Bone and Joint Decade; A. Lyddiatt, Musculoskeletal Group, Cochrane Collaboration; L. March, MD, PhD, University of Sydney Department of Rheumatology, Royal North Shore Hospital; J.E. May, National Fathers’ Network; P. Montie, Arthritis Research Center; A-M. Orbai, MD, Johns Hopkins University; C. Pohl, MD, Schlosspark Klinik; M. Scholte Voshaar, Tools2use.eu; T. Woodworth, David Geffen School of Medicine, University of California at Los Angeles; C.O. Bingham III, MD, Johns Hopkins University; and E.H. Choy, MD, FRCP, Department of Rheumatology, Cardiff University. Address correspondence to Dr. Bykerk, Department of Rheumatology, Hospital for Special Surgery, 535 East 70th St., New York, New York 07030, USA. E-mail: bykerkv@hss.edu
Daniel E. Furst
From the Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Johns Hopkins University, Baltimore, Maryland, USA; McGill University, Montreal, Quebec, Canada; Schlosspark Klinik, Charité University Medicine, Berlin, Germany; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht, The Netherlands; Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark; David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA; University of the West of England, Bristol, UK; Healthy Motivation, Bone and Joint Decade, Santa Barbara, California, USA; Musculoskeletal Group, Cochrane Collaboration; University of Sydney Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; National Fathers’ Network, Seattle, Washington, USA; Arthritis Research Center, Vancouver, British Columbia, Canada; Tools2use.eu, Bussum, The Netherlands; and the Department of Rheumatology, Cardiff University, Cardiff, UK. The OMERACT RA Flare working group received financial and/or logistical and data support from Novartis, Amgen Canada, UCB, and Pfizer. V. Bykerk, principal investigator of the CATCH cohort, has received research grants from, and/or served as a member of advisory boards for, Abbott Laboratories, Amgen, Antares, Astellas, Boehringer Ingelheim, Bristol Meyers Squibb, Janssen Biotech, Pfizer, Merck, Roche, Genentech, and UCB. She is funded by the Cedar Hill Foundation. E. Lie has served on advisory boards for and/or received consultancy/speaker honoraria from Pfizer, Roche, Bristol-Myers Squibb, and Abbvie. R. Alten has received research grants and served as a member of advisory boards and speaker bureaus of Abbott Laboratories, Bristol-Myers Squibb, Chugai Pharma, Horizon, GSK, MSD, Novartis, Pfizer, Roche, Schering Plough, and UCB. C.O. Bingham III has received research grants and/or served as a consultant to Abbott, Amgen, BMS, Celgene, Genentech/Roche, Janssen/Johnson and Johnson/Centocor, Pfizer, and UCB. Work reported in this publication has been supported by the Ira Fine Discovery Fund, the Sibley Hospital Memorial Fund, and the Johns Hopkins Arthritis Center Discovery Fund. S. Bartlett has received consultancy/speaker honoraria from Amgen, Pfizer, Roche, UCB, Biogen, and Abbott; A. Boonen received educational grants from Abbott, MSD, and Amgen and speakers’ honoraria from UCB, Abbott, and Pfizer. R. Christensen has received grant support and/or provided expert advice and/or presentations for Abbott/AbbVie, Axellus, Bayer HealthCare Pharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Cambridge Weight Plan, Ipsen, Laboratoires Expanscience, MSD, Mundipharma, Norpharma, Pfizer, Roche, and Wyeth. L. March is Chair of the Australian Biologics Registry, which receives unrestricted educational grants from Abbott Australasia, Pfizer Australia, Bristol Myers Squibb Australia, and Janssen-Cilag Australasia. A-M. Orbai is supported by the US National Institutes of Health T32-AR48522 and was supported to attend OMERACT 11 by the American College of Rheumatology and the Johns Hopkins Arthritis Center Discovery Fund. D. Furst has received research grants, and served as member of advisory boards and consultancy from Abbott, Actelion, Amgen, BMS, Biogen Idec, Janssen, Gilead, GSK, Novartis, Pfizer, Roche/Genentech, and UCB. He has also a member of the speaker bureau of Abbott, Actelion, and UCB. T. Woodworth is a former employee of Pfizer, Novartis, and Roche/Genentech. E. Choy has received research grants and served as member of advisory boards and speaker bureaus of Abbott Laboratories, Allergan, AstraZeneca, Boehringer Ingelheim, Chelsea Therapeutics, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Ferring Pharmaceutical, GSK, Jazz Pharmaceuticals, MedImmune, Merrimack Pharmaceutical, MSD, Novartis, Pfizer, Pierre Fabre Medicament, Roche, Schering Plough, Synovate, and UCB. V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery; E. Lie, MD, Department of Rheumatology, Diakonhjemmet Hospital; S.J. Bartlett, PhD, Johns Hopkins University, McGill University; R. Alten, MD, Schlosspark Klinik, Charité University Medicine; A. Boonen, MD, PhD, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute; R. Christensen, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital; D.E. Furst, MD, David Geffen School of Medicine, University of California at Los Angeles; S. Hewlett, PhD, RN, University of the West of England, Bristol, UK; A.L. Leong, Healthy Motivation, Bone and Joint Decade; A. Lyddiatt, Musculoskeletal Group, Cochrane Collaboration; L. March, MD, PhD, University of Sydney Department of Rheumatology, Royal North Shore Hospital; J.E. May, National Fathers’ Network; P. Montie, Arthritis Research Center; A-M. Orbai, MD, Johns Hopkins University; C. Pohl, MD, Schlosspark Klinik; M. Scholte Voshaar, Tools2use.eu; T. Woodworth, David Geffen School of Medicine, University of California at Los Angeles; C.O. Bingham III, MD, Johns Hopkins University; and E.H. Choy, MD, FRCP, Department of Rheumatology, Cardiff University. Address correspondence to Dr. Bykerk, Department of Rheumatology, Hospital for Special Surgery, 535 East 70th St., New York, New York 07030, USA. E-mail: bykerkv@hss.edu
Sarah Hewlett
From the Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Johns Hopkins University, Baltimore, Maryland, USA; McGill University, Montreal, Quebec, Canada; Schlosspark Klinik, Charité University Medicine, Berlin, Germany; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht, The Netherlands; Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark; David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA; University of the West of England, Bristol, UK; Healthy Motivation, Bone and Joint Decade, Santa Barbara, California, USA; Musculoskeletal Group, Cochrane Collaboration; University of Sydney Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; National Fathers’ Network, Seattle, Washington, USA; Arthritis Research Center, Vancouver, British Columbia, Canada; Tools2use.eu, Bussum, The Netherlands; and the Department of Rheumatology, Cardiff University, Cardiff, UK. The OMERACT RA Flare working group received financial and/or logistical and data support from Novartis, Amgen Canada, UCB, and Pfizer. V. Bykerk, principal investigator of the CATCH cohort, has received research grants from, and/or served as a member of advisory boards for, Abbott Laboratories, Amgen, Antares, Astellas, Boehringer Ingelheim, Bristol Meyers Squibb, Janssen Biotech, Pfizer, Merck, Roche, Genentech, and UCB. She is funded by the Cedar Hill Foundation. E. Lie has served on advisory boards for and/or received consultancy/speaker honoraria from Pfizer, Roche, Bristol-Myers Squibb, and Abbvie. R. Alten has received research grants and served as a member of advisory boards and speaker bureaus of Abbott Laboratories, Bristol-Myers Squibb, Chugai Pharma, Horizon, GSK, MSD, Novartis, Pfizer, Roche, Schering Plough, and UCB. C.O. Bingham III has received research grants and/or served as a consultant to Abbott, Amgen, BMS, Celgene, Genentech/Roche, Janssen/Johnson and Johnson/Centocor, Pfizer, and UCB. Work reported in this publication has been supported by the Ira Fine Discovery Fund, the Sibley Hospital Memorial Fund, and the Johns Hopkins Arthritis Center Discovery Fund. S. Bartlett has received consultancy/speaker honoraria from Amgen, Pfizer, Roche, UCB, Biogen, and Abbott; A. Boonen received educational grants from Abbott, MSD, and Amgen and speakers’ honoraria from UCB, Abbott, and Pfizer. R. Christensen has received grant support and/or provided expert advice and/or presentations for Abbott/AbbVie, Axellus, Bayer HealthCare Pharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Cambridge Weight Plan, Ipsen, Laboratoires Expanscience, MSD, Mundipharma, Norpharma, Pfizer, Roche, and Wyeth. L. March is Chair of the Australian Biologics Registry, which receives unrestricted educational grants from Abbott Australasia, Pfizer Australia, Bristol Myers Squibb Australia, and Janssen-Cilag Australasia. A-M. Orbai is supported by the US National Institutes of Health T32-AR48522 and was supported to attend OMERACT 11 by the American College of Rheumatology and the Johns Hopkins Arthritis Center Discovery Fund. D. Furst has received research grants, and served as member of advisory boards and consultancy from Abbott, Actelion, Amgen, BMS, Biogen Idec, Janssen, Gilead, GSK, Novartis, Pfizer, Roche/Genentech, and UCB. He has also a member of the speaker bureau of Abbott, Actelion, and UCB. T. Woodworth is a former employee of Pfizer, Novartis, and Roche/Genentech. E. Choy has received research grants and served as member of advisory boards and speaker bureaus of Abbott Laboratories, Allergan, AstraZeneca, Boehringer Ingelheim, Chelsea Therapeutics, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Ferring Pharmaceutical, GSK, Jazz Pharmaceuticals, MedImmune, Merrimack Pharmaceutical, MSD, Novartis, Pfizer, Pierre Fabre Medicament, Roche, Schering Plough, Synovate, and UCB. V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery; E. Lie, MD, Department of Rheumatology, Diakonhjemmet Hospital; S.J. Bartlett, PhD, Johns Hopkins University, McGill University; R. Alten, MD, Schlosspark Klinik, Charité University Medicine; A. Boonen, MD, PhD, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute; R. Christensen, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital; D.E. Furst, MD, David Geffen School of Medicine, University of California at Los Angeles; S. Hewlett, PhD, RN, University of the West of England, Bristol, UK; A.L. Leong, Healthy Motivation, Bone and Joint Decade; A. Lyddiatt, Musculoskeletal Group, Cochrane Collaboration; L. March, MD, PhD, University of Sydney Department of Rheumatology, Royal North Shore Hospital; J.E. May, National Fathers’ Network; P. Montie, Arthritis Research Center; A-M. Orbai, MD, Johns Hopkins University; C. Pohl, MD, Schlosspark Klinik; M. Scholte Voshaar, Tools2use.eu; T. Woodworth, David Geffen School of Medicine, University of California at Los Angeles; C.O. Bingham III, MD, Johns Hopkins University; and E.H. Choy, MD, FRCP, Department of Rheumatology, Cardiff University. Address correspondence to Dr. Bykerk, Department of Rheumatology, Hospital for Special Surgery, 535 East 70th St., New York, New York 07030, USA. E-mail: bykerkv@hss.edu
Amye L. Leong
From the Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Johns Hopkins University, Baltimore, Maryland, USA; McGill University, Montreal, Quebec, Canada; Schlosspark Klinik, Charité University Medicine, Berlin, Germany; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht, The Netherlands; Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark; David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA; University of the West of England, Bristol, UK; Healthy Motivation, Bone and Joint Decade, Santa Barbara, California, USA; Musculoskeletal Group, Cochrane Collaboration; University of Sydney Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; National Fathers’ Network, Seattle, Washington, USA; Arthritis Research Center, Vancouver, British Columbia, Canada; Tools2use.eu, Bussum, The Netherlands; and the Department of Rheumatology, Cardiff University, Cardiff, UK. The OMERACT RA Flare working group received financial and/or logistical and data support from Novartis, Amgen Canada, UCB, and Pfizer. V. Bykerk, principal investigator of the CATCH cohort, has received research grants from, and/or served as a member of advisory boards for, Abbott Laboratories, Amgen, Antares, Astellas, Boehringer Ingelheim, Bristol Meyers Squibb, Janssen Biotech, Pfizer, Merck, Roche, Genentech, and UCB. She is funded by the Cedar Hill Foundation. E. Lie has served on advisory boards for and/or received consultancy/speaker honoraria from Pfizer, Roche, Bristol-Myers Squibb, and Abbvie. R. Alten has received research grants and served as a member of advisory boards and speaker bureaus of Abbott Laboratories, Bristol-Myers Squibb, Chugai Pharma, Horizon, GSK, MSD, Novartis, Pfizer, Roche, Schering Plough, and UCB. C.O. Bingham III has received research grants and/or served as a consultant to Abbott, Amgen, BMS, Celgene, Genentech/Roche, Janssen/Johnson and Johnson/Centocor, Pfizer, and UCB. Work reported in this publication has been supported by the Ira Fine Discovery Fund, the Sibley Hospital Memorial Fund, and the Johns Hopkins Arthritis Center Discovery Fund. S. Bartlett has received consultancy/speaker honoraria from Amgen, Pfizer, Roche, UCB, Biogen, and Abbott; A. Boonen received educational grants from Abbott, MSD, and Amgen and speakers’ honoraria from UCB, Abbott, and Pfizer. R. Christensen has received grant support and/or provided expert advice and/or presentations for Abbott/AbbVie, Axellus, Bayer HealthCare Pharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Cambridge Weight Plan, Ipsen, Laboratoires Expanscience, MSD, Mundipharma, Norpharma, Pfizer, Roche, and Wyeth. L. March is Chair of the Australian Biologics Registry, which receives unrestricted educational grants from Abbott Australasia, Pfizer Australia, Bristol Myers Squibb Australia, and Janssen-Cilag Australasia. A-M. Orbai is supported by the US National Institutes of Health T32-AR48522 and was supported to attend OMERACT 11 by the American College of Rheumatology and the Johns Hopkins Arthritis Center Discovery Fund. D. Furst has received research grants, and served as member of advisory boards and consultancy from Abbott, Actelion, Amgen, BMS, Biogen Idec, Janssen, Gilead, GSK, Novartis, Pfizer, Roche/Genentech, and UCB. He has also a member of the speaker bureau of Abbott, Actelion, and UCB. T. Woodworth is a former employee of Pfizer, Novartis, and Roche/Genentech. E. Choy has received research grants and served as member of advisory boards and speaker bureaus of Abbott Laboratories, Allergan, AstraZeneca, Boehringer Ingelheim, Chelsea Therapeutics, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Ferring Pharmaceutical, GSK, Jazz Pharmaceuticals, MedImmune, Merrimack Pharmaceutical, MSD, Novartis, Pfizer, Pierre Fabre Medicament, Roche, Schering Plough, Synovate, and UCB. V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery; E. Lie, MD, Department of Rheumatology, Diakonhjemmet Hospital; S.J. Bartlett, PhD, Johns Hopkins University, McGill University; R. Alten, MD, Schlosspark Klinik, Charité University Medicine; A. Boonen, MD, PhD, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute; R. Christensen, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital; D.E. Furst, MD, David Geffen School of Medicine, University of California at Los Angeles; S. Hewlett, PhD, RN, University of the West of England, Bristol, UK; A.L. Leong, Healthy Motivation, Bone and Joint Decade; A. Lyddiatt, Musculoskeletal Group, Cochrane Collaboration; L. March, MD, PhD, University of Sydney Department of Rheumatology, Royal North Shore Hospital; J.E. May, National Fathers’ Network; P. Montie, Arthritis Research Center; A-M. Orbai, MD, Johns Hopkins University; C. Pohl, MD, Schlosspark Klinik; M. Scholte Voshaar, Tools2use.eu; T. Woodworth, David Geffen School of Medicine, University of California at Los Angeles; C.O. Bingham III, MD, Johns Hopkins University; and E.H. Choy, MD, FRCP, Department of Rheumatology, Cardiff University. Address correspondence to Dr. Bykerk, Department of Rheumatology, Hospital for Special Surgery, 535 East 70th St., New York, New York 07030, USA. E-mail: bykerkv@hss.edu
Anne Lyddiatt
From the Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Johns Hopkins University, Baltimore, Maryland, USA; McGill University, Montreal, Quebec, Canada; Schlosspark Klinik, Charité University Medicine, Berlin, Germany; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht, The Netherlands; Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark; David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA; University of the West of England, Bristol, UK; Healthy Motivation, Bone and Joint Decade, Santa Barbara, California, USA; Musculoskeletal Group, Cochrane Collaboration; University of Sydney Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; National Fathers’ Network, Seattle, Washington, USA; Arthritis Research Center, Vancouver, British Columbia, Canada; Tools2use.eu, Bussum, The Netherlands; and the Department of Rheumatology, Cardiff University, Cardiff, UK. The OMERACT RA Flare working group received financial and/or logistical and data support from Novartis, Amgen Canada, UCB, and Pfizer. V. Bykerk, principal investigator of the CATCH cohort, has received research grants from, and/or served as a member of advisory boards for, Abbott Laboratories, Amgen, Antares, Astellas, Boehringer Ingelheim, Bristol Meyers Squibb, Janssen Biotech, Pfizer, Merck, Roche, Genentech, and UCB. She is funded by the Cedar Hill Foundation. E. Lie has served on advisory boards for and/or received consultancy/speaker honoraria from Pfizer, Roche, Bristol-Myers Squibb, and Abbvie. R. Alten has received research grants and served as a member of advisory boards and speaker bureaus of Abbott Laboratories, Bristol-Myers Squibb, Chugai Pharma, Horizon, GSK, MSD, Novartis, Pfizer, Roche, Schering Plough, and UCB. C.O. Bingham III has received research grants and/or served as a consultant to Abbott, Amgen, BMS, Celgene, Genentech/Roche, Janssen/Johnson and Johnson/Centocor, Pfizer, and UCB. Work reported in this publication has been supported by the Ira Fine Discovery Fund, the Sibley Hospital Memorial Fund, and the Johns Hopkins Arthritis Center Discovery Fund. S. Bartlett has received consultancy/speaker honoraria from Amgen, Pfizer, Roche, UCB, Biogen, and Abbott; A. Boonen received educational grants from Abbott, MSD, and Amgen and speakers’ honoraria from UCB, Abbott, and Pfizer. R. Christensen has received grant support and/or provided expert advice and/or presentations for Abbott/AbbVie, Axellus, Bayer HealthCare Pharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Cambridge Weight Plan, Ipsen, Laboratoires Expanscience, MSD, Mundipharma, Norpharma, Pfizer, Roche, and Wyeth. L. March is Chair of the Australian Biologics Registry, which receives unrestricted educational grants from Abbott Australasia, Pfizer Australia, Bristol Myers Squibb Australia, and Janssen-Cilag Australasia. A-M. Orbai is supported by the US National Institutes of Health T32-AR48522 and was supported to attend OMERACT 11 by the American College of Rheumatology and the Johns Hopkins Arthritis Center Discovery Fund. D. Furst has received research grants, and served as member of advisory boards and consultancy from Abbott, Actelion, Amgen, BMS, Biogen Idec, Janssen, Gilead, GSK, Novartis, Pfizer, Roche/Genentech, and UCB. He has also a member of the speaker bureau of Abbott, Actelion, and UCB. T. Woodworth is a former employee of Pfizer, Novartis, and Roche/Genentech. E. Choy has received research grants and served as member of advisory boards and speaker bureaus of Abbott Laboratories, Allergan, AstraZeneca, Boehringer Ingelheim, Chelsea Therapeutics, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Ferring Pharmaceutical, GSK, Jazz Pharmaceuticals, MedImmune, Merrimack Pharmaceutical, MSD, Novartis, Pfizer, Pierre Fabre Medicament, Roche, Schering Plough, Synovate, and UCB. V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery; E. Lie, MD, Department of Rheumatology, Diakonhjemmet Hospital; S.J. Bartlett, PhD, Johns Hopkins University, McGill University; R. Alten, MD, Schlosspark Klinik, Charité University Medicine; A. Boonen, MD, PhD, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute; R. Christensen, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital; D.E. Furst, MD, David Geffen School of Medicine, University of California at Los Angeles; S. Hewlett, PhD, RN, University of the West of England, Bristol, UK; A.L. Leong, Healthy Motivation, Bone and Joint Decade; A. Lyddiatt, Musculoskeletal Group, Cochrane Collaboration; L. March, MD, PhD, University of Sydney Department of Rheumatology, Royal North Shore Hospital; J.E. May, National Fathers’ Network; P. Montie, Arthritis Research Center; A-M. Orbai, MD, Johns Hopkins University; C. Pohl, MD, Schlosspark Klinik; M. Scholte Voshaar, Tools2use.eu; T. Woodworth, David Geffen School of Medicine, University of California at Los Angeles; C.O. Bingham III, MD, Johns Hopkins University; and E.H. Choy, MD, FRCP, Department of Rheumatology, Cardiff University. Address correspondence to Dr. Bykerk, Department of Rheumatology, Hospital for Special Surgery, 535 East 70th St., New York, New York 07030, USA. E-mail: bykerkv@hss.edu
Lyn March
From the Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Johns Hopkins University, Baltimore, Maryland, USA; McGill University, Montreal, Quebec, Canada; Schlosspark Klinik, Charité University Medicine, Berlin, Germany; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht, The Netherlands; Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark; David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA; University of the West of England, Bristol, UK; Healthy Motivation, Bone and Joint Decade, Santa Barbara, California, USA; Musculoskeletal Group, Cochrane Collaboration; University of Sydney Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; National Fathers’ Network, Seattle, Washington, USA; Arthritis Research Center, Vancouver, British Columbia, Canada; Tools2use.eu, Bussum, The Netherlands; and the Department of Rheumatology, Cardiff University, Cardiff, UK. The OMERACT RA Flare working group received financial and/or logistical and data support from Novartis, Amgen Canada, UCB, and Pfizer. V. Bykerk, principal investigator of the CATCH cohort, has received research grants from, and/or served as a member of advisory boards for, Abbott Laboratories, Amgen, Antares, Astellas, Boehringer Ingelheim, Bristol Meyers Squibb, Janssen Biotech, Pfizer, Merck, Roche, Genentech, and UCB. She is funded by the Cedar Hill Foundation. E. Lie has served on advisory boards for and/or received consultancy/speaker honoraria from Pfizer, Roche, Bristol-Myers Squibb, and Abbvie. R. Alten has received research grants and served as a member of advisory boards and speaker bureaus of Abbott Laboratories, Bristol-Myers Squibb, Chugai Pharma, Horizon, GSK, MSD, Novartis, Pfizer, Roche, Schering Plough, and UCB. C.O. Bingham III has received research grants and/or served as a consultant to Abbott, Amgen, BMS, Celgene, Genentech/Roche, Janssen/Johnson and Johnson/Centocor, Pfizer, and UCB. Work reported in this publication has been supported by the Ira Fine Discovery Fund, the Sibley Hospital Memorial Fund, and the Johns Hopkins Arthritis Center Discovery Fund. S. Bartlett has received consultancy/speaker honoraria from Amgen, Pfizer, Roche, UCB, Biogen, and Abbott; A. Boonen received educational grants from Abbott, MSD, and Amgen and speakers’ honoraria from UCB, Abbott, and Pfizer. R. Christensen has received grant support and/or provided expert advice and/or presentations for Abbott/AbbVie, Axellus, Bayer HealthCare Pharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Cambridge Weight Plan, Ipsen, Laboratoires Expanscience, MSD, Mundipharma, Norpharma, Pfizer, Roche, and Wyeth. L. March is Chair of the Australian Biologics Registry, which receives unrestricted educational grants from Abbott Australasia, Pfizer Australia, Bristol Myers Squibb Australia, and Janssen-Cilag Australasia. A-M. Orbai is supported by the US National Institutes of Health T32-AR48522 and was supported to attend OMERACT 11 by the American College of Rheumatology and the Johns Hopkins Arthritis Center Discovery Fund. D. Furst has received research grants, and served as member of advisory boards and consultancy from Abbott, Actelion, Amgen, BMS, Biogen Idec, Janssen, Gilead, GSK, Novartis, Pfizer, Roche/Genentech, and UCB. He has also a member of the speaker bureau of Abbott, Actelion, and UCB. T. Woodworth is a former employee of Pfizer, Novartis, and Roche/Genentech. E. Choy has received research grants and served as member of advisory boards and speaker bureaus of Abbott Laboratories, Allergan, AstraZeneca, Boehringer Ingelheim, Chelsea Therapeutics, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Ferring Pharmaceutical, GSK, Jazz Pharmaceuticals, MedImmune, Merrimack Pharmaceutical, MSD, Novartis, Pfizer, Pierre Fabre Medicament, Roche, Schering Plough, Synovate, and UCB. V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery; E. Lie, MD, Department of Rheumatology, Diakonhjemmet Hospital; S.J. Bartlett, PhD, Johns Hopkins University, McGill University; R. Alten, MD, Schlosspark Klinik, Charité University Medicine; A. Boonen, MD, PhD, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute; R. Christensen, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital; D.E. Furst, MD, David Geffen School of Medicine, University of California at Los Angeles; S. Hewlett, PhD, RN, University of the West of England, Bristol, UK; A.L. Leong, Healthy Motivation, Bone and Joint Decade; A. Lyddiatt, Musculoskeletal Group, Cochrane Collaboration; L. March, MD, PhD, University of Sydney Department of Rheumatology, Royal North Shore Hospital; J.E. May, National Fathers’ Network; P. Montie, Arthritis Research Center; A-M. Orbai, MD, Johns Hopkins University; C. Pohl, MD, Schlosspark Klinik; M. Scholte Voshaar, Tools2use.eu; T. Woodworth, David Geffen School of Medicine, University of California at Los Angeles; C.O. Bingham III, MD, Johns Hopkins University; and E.H. Choy, MD, FRCP, Department of Rheumatology, Cardiff University. Address correspondence to Dr. Bykerk, Department of Rheumatology, Hospital for Special Surgery, 535 East 70th St., New York, New York 07030, USA. E-mail: bykerkv@hss.edu
James E. May
From the Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Johns Hopkins University, Baltimore, Maryland, USA; McGill University, Montreal, Quebec, Canada; Schlosspark Klinik, Charité University Medicine, Berlin, Germany; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht, The Netherlands; Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark; David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA; University of the West of England, Bristol, UK; Healthy Motivation, Bone and Joint Decade, Santa Barbara, California, USA; Musculoskeletal Group, Cochrane Collaboration; University of Sydney Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; National Fathers’ Network, Seattle, Washington, USA; Arthritis Research Center, Vancouver, British Columbia, Canada; Tools2use.eu, Bussum, The Netherlands; and the Department of Rheumatology, Cardiff University, Cardiff, UK. The OMERACT RA Flare working group received financial and/or logistical and data support from Novartis, Amgen Canada, UCB, and Pfizer. V. Bykerk, principal investigator of the CATCH cohort, has received research grants from, and/or served as a member of advisory boards for, Abbott Laboratories, Amgen, Antares, Astellas, Boehringer Ingelheim, Bristol Meyers Squibb, Janssen Biotech, Pfizer, Merck, Roche, Genentech, and UCB. She is funded by the Cedar Hill Foundation. E. Lie has served on advisory boards for and/or received consultancy/speaker honoraria from Pfizer, Roche, Bristol-Myers Squibb, and Abbvie. R. Alten has received research grants and served as a member of advisory boards and speaker bureaus of Abbott Laboratories, Bristol-Myers Squibb, Chugai Pharma, Horizon, GSK, MSD, Novartis, Pfizer, Roche, Schering Plough, and UCB. C.O. Bingham III has received research grants and/or served as a consultant to Abbott, Amgen, BMS, Celgene, Genentech/Roche, Janssen/Johnson and Johnson/Centocor, Pfizer, and UCB. Work reported in this publication has been supported by the Ira Fine Discovery Fund, the Sibley Hospital Memorial Fund, and the Johns Hopkins Arthritis Center Discovery Fund. S. Bartlett has received consultancy/speaker honoraria from Amgen, Pfizer, Roche, UCB, Biogen, and Abbott; A. Boonen received educational grants from Abbott, MSD, and Amgen and speakers’ honoraria from UCB, Abbott, and Pfizer. R. Christensen has received grant support and/or provided expert advice and/or presentations for Abbott/AbbVie, Axellus, Bayer HealthCare Pharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Cambridge Weight Plan, Ipsen, Laboratoires Expanscience, MSD, Mundipharma, Norpharma, Pfizer, Roche, and Wyeth. L. March is Chair of the Australian Biologics Registry, which receives unrestricted educational grants from Abbott Australasia, Pfizer Australia, Bristol Myers Squibb Australia, and Janssen-Cilag Australasia. A-M. Orbai is supported by the US National Institutes of Health T32-AR48522 and was supported to attend OMERACT 11 by the American College of Rheumatology and the Johns Hopkins Arthritis Center Discovery Fund. D. Furst has received research grants, and served as member of advisory boards and consultancy from Abbott, Actelion, Amgen, BMS, Biogen Idec, Janssen, Gilead, GSK, Novartis, Pfizer, Roche/Genentech, and UCB. He has also a member of the speaker bureau of Abbott, Actelion, and UCB. T. Woodworth is a former employee of Pfizer, Novartis, and Roche/Genentech. E. Choy has received research grants and served as member of advisory boards and speaker bureaus of Abbott Laboratories, Allergan, AstraZeneca, Boehringer Ingelheim, Chelsea Therapeutics, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Ferring Pharmaceutical, GSK, Jazz Pharmaceuticals, MedImmune, Merrimack Pharmaceutical, MSD, Novartis, Pfizer, Pierre Fabre Medicament, Roche, Schering Plough, Synovate, and UCB. V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery; E. Lie, MD, Department of Rheumatology, Diakonhjemmet Hospital; S.J. Bartlett, PhD, Johns Hopkins University, McGill University; R. Alten, MD, Schlosspark Klinik, Charité University Medicine; A. Boonen, MD, PhD, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute; R. Christensen, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital; D.E. Furst, MD, David Geffen School of Medicine, University of California at Los Angeles; S. Hewlett, PhD, RN, University of the West of England, Bristol, UK; A.L. Leong, Healthy Motivation, Bone and Joint Decade; A. Lyddiatt, Musculoskeletal Group, Cochrane Collaboration; L. March, MD, PhD, University of Sydney Department of Rheumatology, Royal North Shore Hospital; J.E. May, National Fathers’ Network; P. Montie, Arthritis Research Center; A-M. Orbai, MD, Johns Hopkins University; C. Pohl, MD, Schlosspark Klinik; M. Scholte Voshaar, Tools2use.eu; T. Woodworth, David Geffen School of Medicine, University of California at Los Angeles; C.O. Bingham III, MD, Johns Hopkins University; and E.H. Choy, MD, FRCP, Department of Rheumatology, Cardiff University. Address correspondence to Dr. Bykerk, Department of Rheumatology, Hospital for Special Surgery, 535 East 70th St., New York, New York 07030, USA. E-mail: bykerkv@hss.edu
Pam Montie
From the Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Johns Hopkins University, Baltimore, Maryland, USA; McGill University, Montreal, Quebec, Canada; Schlosspark Klinik, Charité University Medicine, Berlin, Germany; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht, The Netherlands; Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark; David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA; University of the West of England, Bristol, UK; Healthy Motivation, Bone and Joint Decade, Santa Barbara, California, USA; Musculoskeletal Group, Cochrane Collaboration; University of Sydney Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; National Fathers’ Network, Seattle, Washington, USA; Arthritis Research Center, Vancouver, British Columbia, Canada; Tools2use.eu, Bussum, The Netherlands; and the Department of Rheumatology, Cardiff University, Cardiff, UK. The OMERACT RA Flare working group received financial and/or logistical and data support from Novartis, Amgen Canada, UCB, and Pfizer. V. Bykerk, principal investigator of the CATCH cohort, has received research grants from, and/or served as a member of advisory boards for, Abbott Laboratories, Amgen, Antares, Astellas, Boehringer Ingelheim, Bristol Meyers Squibb, Janssen Biotech, Pfizer, Merck, Roche, Genentech, and UCB. She is funded by the Cedar Hill Foundation. E. Lie has served on advisory boards for and/or received consultancy/speaker honoraria from Pfizer, Roche, Bristol-Myers Squibb, and Abbvie. R. Alten has received research grants and served as a member of advisory boards and speaker bureaus of Abbott Laboratories, Bristol-Myers Squibb, Chugai Pharma, Horizon, GSK, MSD, Novartis, Pfizer, Roche, Schering Plough, and UCB. C.O. Bingham III has received research grants and/or served as a consultant to Abbott, Amgen, BMS, Celgene, Genentech/Roche, Janssen/Johnson and Johnson/Centocor, Pfizer, and UCB. Work reported in this publication has been supported by the Ira Fine Discovery Fund, the Sibley Hospital Memorial Fund, and the Johns Hopkins Arthritis Center Discovery Fund. S. Bartlett has received consultancy/speaker honoraria from Amgen, Pfizer, Roche, UCB, Biogen, and Abbott; A. Boonen received educational grants from Abbott, MSD, and Amgen and speakers’ honoraria from UCB, Abbott, and Pfizer. R. Christensen has received grant support and/or provided expert advice and/or presentations for Abbott/AbbVie, Axellus, Bayer HealthCare Pharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Cambridge Weight Plan, Ipsen, Laboratoires Expanscience, MSD, Mundipharma, Norpharma, Pfizer, Roche, and Wyeth. L. March is Chair of the Australian Biologics Registry, which receives unrestricted educational grants from Abbott Australasia, Pfizer Australia, Bristol Myers Squibb Australia, and Janssen-Cilag Australasia. A-M. Orbai is supported by the US National Institutes of Health T32-AR48522 and was supported to attend OMERACT 11 by the American College of Rheumatology and the Johns Hopkins Arthritis Center Discovery Fund. D. Furst has received research grants, and served as member of advisory boards and consultancy from Abbott, Actelion, Amgen, BMS, Biogen Idec, Janssen, Gilead, GSK, Novartis, Pfizer, Roche/Genentech, and UCB. He has also a member of the speaker bureau of Abbott, Actelion, and UCB. T. Woodworth is a former employee of Pfizer, Novartis, and Roche/Genentech. E. Choy has received research grants and served as member of advisory boards and speaker bureaus of Abbott Laboratories, Allergan, AstraZeneca, Boehringer Ingelheim, Chelsea Therapeutics, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Ferring Pharmaceutical, GSK, Jazz Pharmaceuticals, MedImmune, Merrimack Pharmaceutical, MSD, Novartis, Pfizer, Pierre Fabre Medicament, Roche, Schering Plough, Synovate, and UCB. V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery; E. Lie, MD, Department of Rheumatology, Diakonhjemmet Hospital; S.J. Bartlett, PhD, Johns Hopkins University, McGill University; R. Alten, MD, Schlosspark Klinik, Charité University Medicine; A. Boonen, MD, PhD, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute; R. Christensen, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital; D.E. Furst, MD, David Geffen School of Medicine, University of California at Los Angeles; S. Hewlett, PhD, RN, University of the West of England, Bristol, UK; A.L. Leong, Healthy Motivation, Bone and Joint Decade; A. Lyddiatt, Musculoskeletal Group, Cochrane Collaboration; L. March, MD, PhD, University of Sydney Department of Rheumatology, Royal North Shore Hospital; J.E. May, National Fathers’ Network; P. Montie, Arthritis Research Center; A-M. Orbai, MD, Johns Hopkins University; C. Pohl, MD, Schlosspark Klinik; M. Scholte Voshaar, Tools2use.eu; T. Woodworth, David Geffen School of Medicine, University of California at Los Angeles; C.O. Bingham III, MD, Johns Hopkins University; and E.H. Choy, MD, FRCP, Department of Rheumatology, Cardiff University. Address correspondence to Dr. Bykerk, Department of Rheumatology, Hospital for Special Surgery, 535 East 70th St., New York, New York 07030, USA. E-mail: bykerkv@hss.edu
Ana-Maria Orbai
From the Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Johns Hopkins University, Baltimore, Maryland, USA; McGill University, Montreal, Quebec, Canada; Schlosspark Klinik, Charité University Medicine, Berlin, Germany; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht, The Netherlands; Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark; David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA; University of the West of England, Bristol, UK; Healthy Motivation, Bone and Joint Decade, Santa Barbara, California, USA; Musculoskeletal Group, Cochrane Collaboration; University of Sydney Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; National Fathers’ Network, Seattle, Washington, USA; Arthritis Research Center, Vancouver, British Columbia, Canada; Tools2use.eu, Bussum, The Netherlands; and the Department of Rheumatology, Cardiff University, Cardiff, UK. The OMERACT RA Flare working group received financial and/or logistical and data support from Novartis, Amgen Canada, UCB, and Pfizer. V. Bykerk, principal investigator of the CATCH cohort, has received research grants from, and/or served as a member of advisory boards for, Abbott Laboratories, Amgen, Antares, Astellas, Boehringer Ingelheim, Bristol Meyers Squibb, Janssen Biotech, Pfizer, Merck, Roche, Genentech, and UCB. She is funded by the Cedar Hill Foundation. E. Lie has served on advisory boards for and/or received consultancy/speaker honoraria from Pfizer, Roche, Bristol-Myers Squibb, and Abbvie. R. Alten has received research grants and served as a member of advisory boards and speaker bureaus of Abbott Laboratories, Bristol-Myers Squibb, Chugai Pharma, Horizon, GSK, MSD, Novartis, Pfizer, Roche, Schering Plough, and UCB. C.O. Bingham III has received research grants and/or served as a consultant to Abbott, Amgen, BMS, Celgene, Genentech/Roche, Janssen/Johnson and Johnson/Centocor, Pfizer, and UCB. Work reported in this publication has been supported by the Ira Fine Discovery Fund, the Sibley Hospital Memorial Fund, and the Johns Hopkins Arthritis Center Discovery Fund. S. Bartlett has received consultancy/speaker honoraria from Amgen, Pfizer, Roche, UCB, Biogen, and Abbott; A. Boonen received educational grants from Abbott, MSD, and Amgen and speakers’ honoraria from UCB, Abbott, and Pfizer. R. Christensen has received grant support and/or provided expert advice and/or presentations for Abbott/AbbVie, Axellus, Bayer HealthCare Pharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Cambridge Weight Plan, Ipsen, Laboratoires Expanscience, MSD, Mundipharma, Norpharma, Pfizer, Roche, and Wyeth. L. March is Chair of the Australian Biologics Registry, which receives unrestricted educational grants from Abbott Australasia, Pfizer Australia, Bristol Myers Squibb Australia, and Janssen-Cilag Australasia. A-M. Orbai is supported by the US National Institutes of Health T32-AR48522 and was supported to attend OMERACT 11 by the American College of Rheumatology and the Johns Hopkins Arthritis Center Discovery Fund. D. Furst has received research grants, and served as member of advisory boards and consultancy from Abbott, Actelion, Amgen, BMS, Biogen Idec, Janssen, Gilead, GSK, Novartis, Pfizer, Roche/Genentech, and UCB. He has also a member of the speaker bureau of Abbott, Actelion, and UCB. T. Woodworth is a former employee of Pfizer, Novartis, and Roche/Genentech. E. Choy has received research grants and served as member of advisory boards and speaker bureaus of Abbott Laboratories, Allergan, AstraZeneca, Boehringer Ingelheim, Chelsea Therapeutics, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Ferring Pharmaceutical, GSK, Jazz Pharmaceuticals, MedImmune, Merrimack Pharmaceutical, MSD, Novartis, Pfizer, Pierre Fabre Medicament, Roche, Schering Plough, Synovate, and UCB. V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery; E. Lie, MD, Department of Rheumatology, Diakonhjemmet Hospital; S.J. Bartlett, PhD, Johns Hopkins University, McGill University; R. Alten, MD, Schlosspark Klinik, Charité University Medicine; A. Boonen, MD, PhD, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute; R. Christensen, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital; D.E. Furst, MD, David Geffen School of Medicine, University of California at Los Angeles; S. Hewlett, PhD, RN, University of the West of England, Bristol, UK; A.L. Leong, Healthy Motivation, Bone and Joint Decade; A. Lyddiatt, Musculoskeletal Group, Cochrane Collaboration; L. March, MD, PhD, University of Sydney Department of Rheumatology, Royal North Shore Hospital; J.E. May, National Fathers’ Network; P. Montie, Arthritis Research Center; A-M. Orbai, MD, Johns Hopkins University; C. Pohl, MD, Schlosspark Klinik; M. Scholte Voshaar, Tools2use.eu; T. Woodworth, David Geffen School of Medicine, University of California at Los Angeles; C.O. Bingham III, MD, Johns Hopkins University; and E.H. Choy, MD, FRCP, Department of Rheumatology, Cardiff University. Address correspondence to Dr. Bykerk, Department of Rheumatology, Hospital for Special Surgery, 535 East 70th St., New York, New York 07030, USA. E-mail: bykerkv@hss.edu
Christoph Pohl
From the Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Johns Hopkins University, Baltimore, Maryland, USA; McGill University, Montreal, Quebec, Canada; Schlosspark Klinik, Charité University Medicine, Berlin, Germany; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht, The Netherlands; Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark; David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA; University of the West of England, Bristol, UK; Healthy Motivation, Bone and Joint Decade, Santa Barbara, California, USA; Musculoskeletal Group, Cochrane Collaboration; University of Sydney Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; National Fathers’ Network, Seattle, Washington, USA; Arthritis Research Center, Vancouver, British Columbia, Canada; Tools2use.eu, Bussum, The Netherlands; and the Department of Rheumatology, Cardiff University, Cardiff, UK. The OMERACT RA Flare working group received financial and/or logistical and data support from Novartis, Amgen Canada, UCB, and Pfizer. V. Bykerk, principal investigator of the CATCH cohort, has received research grants from, and/or served as a member of advisory boards for, Abbott Laboratories, Amgen, Antares, Astellas, Boehringer Ingelheim, Bristol Meyers Squibb, Janssen Biotech, Pfizer, Merck, Roche, Genentech, and UCB. She is funded by the Cedar Hill Foundation. E. Lie has served on advisory boards for and/or received consultancy/speaker honoraria from Pfizer, Roche, Bristol-Myers Squibb, and Abbvie. R. Alten has received research grants and served as a member of advisory boards and speaker bureaus of Abbott Laboratories, Bristol-Myers Squibb, Chugai Pharma, Horizon, GSK, MSD, Novartis, Pfizer, Roche, Schering Plough, and UCB. C.O. Bingham III has received research grants and/or served as a consultant to Abbott, Amgen, BMS, Celgene, Genentech/Roche, Janssen/Johnson and Johnson/Centocor, Pfizer, and UCB. Work reported in this publication has been supported by the Ira Fine Discovery Fund, the Sibley Hospital Memorial Fund, and the Johns Hopkins Arthritis Center Discovery Fund. S. Bartlett has received consultancy/speaker honoraria from Amgen, Pfizer, Roche, UCB, Biogen, and Abbott; A. Boonen received educational grants from Abbott, MSD, and Amgen and speakers’ honoraria from UCB, Abbott, and Pfizer. R. Christensen has received grant support and/or provided expert advice and/or presentations for Abbott/AbbVie, Axellus, Bayer HealthCare Pharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Cambridge Weight Plan, Ipsen, Laboratoires Expanscience, MSD, Mundipharma, Norpharma, Pfizer, Roche, and Wyeth. L. March is Chair of the Australian Biologics Registry, which receives unrestricted educational grants from Abbott Australasia, Pfizer Australia, Bristol Myers Squibb Australia, and Janssen-Cilag Australasia. A-M. Orbai is supported by the US National Institutes of Health T32-AR48522 and was supported to attend OMERACT 11 by the American College of Rheumatology and the Johns Hopkins Arthritis Center Discovery Fund. D. Furst has received research grants, and served as member of advisory boards and consultancy from Abbott, Actelion, Amgen, BMS, Biogen Idec, Janssen, Gilead, GSK, Novartis, Pfizer, Roche/Genentech, and UCB. He has also a member of the speaker bureau of Abbott, Actelion, and UCB. T. Woodworth is a former employee of Pfizer, Novartis, and Roche/Genentech. E. Choy has received research grants and served as member of advisory boards and speaker bureaus of Abbott Laboratories, Allergan, AstraZeneca, Boehringer Ingelheim, Chelsea Therapeutics, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Ferring Pharmaceutical, GSK, Jazz Pharmaceuticals, MedImmune, Merrimack Pharmaceutical, MSD, Novartis, Pfizer, Pierre Fabre Medicament, Roche, Schering Plough, Synovate, and UCB. V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery; E. Lie, MD, Department of Rheumatology, Diakonhjemmet Hospital; S.J. Bartlett, PhD, Johns Hopkins University, McGill University; R. Alten, MD, Schlosspark Klinik, Charité University Medicine; A. Boonen, MD, PhD, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute; R. Christensen, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital; D.E. Furst, MD, David Geffen School of Medicine, University of California at Los Angeles; S. Hewlett, PhD, RN, University of the West of England, Bristol, UK; A.L. Leong, Healthy Motivation, Bone and Joint Decade; A. Lyddiatt, Musculoskeletal Group, Cochrane Collaboration; L. March, MD, PhD, University of Sydney Department of Rheumatology, Royal North Shore Hospital; J.E. May, National Fathers’ Network; P. Montie, Arthritis Research Center; A-M. Orbai, MD, Johns Hopkins University; C. Pohl, MD, Schlosspark Klinik; M. Scholte Voshaar, Tools2use.eu; T. Woodworth, David Geffen School of Medicine, University of California at Los Angeles; C.O. Bingham III, MD, Johns Hopkins University; and E.H. Choy, MD, FRCP, Department of Rheumatology, Cardiff University. Address correspondence to Dr. Bykerk, Department of Rheumatology, Hospital for Special Surgery, 535 East 70th St., New York, New York 07030, USA. E-mail: bykerkv@hss.edu
Marieke Scholte Voshaar
From the Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Johns Hopkins University, Baltimore, Maryland, USA; McGill University, Montreal, Quebec, Canada; Schlosspark Klinik, Charité University Medicine, Berlin, Germany; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht, The Netherlands; Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark; David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA; University of the West of England, Bristol, UK; Healthy Motivation, Bone and Joint Decade, Santa Barbara, California, USA; Musculoskeletal Group, Cochrane Collaboration; University of Sydney Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; National Fathers’ Network, Seattle, Washington, USA; Arthritis Research Center, Vancouver, British Columbia, Canada; Tools2use.eu, Bussum, The Netherlands; and the Department of Rheumatology, Cardiff University, Cardiff, UK. The OMERACT RA Flare working group received financial and/or logistical and data support from Novartis, Amgen Canada, UCB, and Pfizer. V. Bykerk, principal investigator of the CATCH cohort, has received research grants from, and/or served as a member of advisory boards for, Abbott Laboratories, Amgen, Antares, Astellas, Boehringer Ingelheim, Bristol Meyers Squibb, Janssen Biotech, Pfizer, Merck, Roche, Genentech, and UCB. She is funded by the Cedar Hill Foundation. E. Lie has served on advisory boards for and/or received consultancy/speaker honoraria from Pfizer, Roche, Bristol-Myers Squibb, and Abbvie. R. Alten has received research grants and served as a member of advisory boards and speaker bureaus of Abbott Laboratories, Bristol-Myers Squibb, Chugai Pharma, Horizon, GSK, MSD, Novartis, Pfizer, Roche, Schering Plough, and UCB. C.O. Bingham III has received research grants and/or served as a consultant to Abbott, Amgen, BMS, Celgene, Genentech/Roche, Janssen/Johnson and Johnson/Centocor, Pfizer, and UCB. Work reported in this publication has been supported by the Ira Fine Discovery Fund, the Sibley Hospital Memorial Fund, and the Johns Hopkins Arthritis Center Discovery Fund. S. Bartlett has received consultancy/speaker honoraria from Amgen, Pfizer, Roche, UCB, Biogen, and Abbott; A. Boonen received educational grants from Abbott, MSD, and Amgen and speakers’ honoraria from UCB, Abbott, and Pfizer. R. Christensen has received grant support and/or provided expert advice and/or presentations for Abbott/AbbVie, Axellus, Bayer HealthCare Pharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Cambridge Weight Plan, Ipsen, Laboratoires Expanscience, MSD, Mundipharma, Norpharma, Pfizer, Roche, and Wyeth. L. March is Chair of the Australian Biologics Registry, which receives unrestricted educational grants from Abbott Australasia, Pfizer Australia, Bristol Myers Squibb Australia, and Janssen-Cilag Australasia. A-M. Orbai is supported by the US National Institutes of Health T32-AR48522 and was supported to attend OMERACT 11 by the American College of Rheumatology and the Johns Hopkins Arthritis Center Discovery Fund. D. Furst has received research grants, and served as member of advisory boards and consultancy from Abbott, Actelion, Amgen, BMS, Biogen Idec, Janssen, Gilead, GSK, Novartis, Pfizer, Roche/Genentech, and UCB. He has also a member of the speaker bureau of Abbott, Actelion, and UCB. T. Woodworth is a former employee of Pfizer, Novartis, and Roche/Genentech. E. Choy has received research grants and served as member of advisory boards and speaker bureaus of Abbott Laboratories, Allergan, AstraZeneca, Boehringer Ingelheim, Chelsea Therapeutics, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Ferring Pharmaceutical, GSK, Jazz Pharmaceuticals, MedImmune, Merrimack Pharmaceutical, MSD, Novartis, Pfizer, Pierre Fabre Medicament, Roche, Schering Plough, Synovate, and UCB. V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery; E. Lie, MD, Department of Rheumatology, Diakonhjemmet Hospital; S.J. Bartlett, PhD, Johns Hopkins University, McGill University; R. Alten, MD, Schlosspark Klinik, Charité University Medicine; A. Boonen, MD, PhD, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute; R. Christensen, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital; D.E. Furst, MD, David Geffen School of Medicine, University of California at Los Angeles; S. Hewlett, PhD, RN, University of the West of England, Bristol, UK; A.L. Leong, Healthy Motivation, Bone and Joint Decade; A. Lyddiatt, Musculoskeletal Group, Cochrane Collaboration; L. March, MD, PhD, University of Sydney Department of Rheumatology, Royal North Shore Hospital; J.E. May, National Fathers’ Network; P. Montie, Arthritis Research Center; A-M. Orbai, MD, Johns Hopkins University; C. Pohl, MD, Schlosspark Klinik; M. Scholte Voshaar, Tools2use.eu; T. Woodworth, David Geffen School of Medicine, University of California at Los Angeles; C.O. Bingham III, MD, Johns Hopkins University; and E.H. Choy, MD, FRCP, Department of Rheumatology, Cardiff University. Address correspondence to Dr. Bykerk, Department of Rheumatology, Hospital for Special Surgery, 535 East 70th St., New York, New York 07030, USA. E-mail: bykerkv@hss.edu
Thasia Woodworth
From the Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Johns Hopkins University, Baltimore, Maryland, USA; McGill University, Montreal, Quebec, Canada; Schlosspark Klinik, Charité University Medicine, Berlin, Germany; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht, The Netherlands; Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark; David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA; University of the West of England, Bristol, UK; Healthy Motivation, Bone and Joint Decade, Santa Barbara, California, USA; Musculoskeletal Group, Cochrane Collaboration; University of Sydney Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; National Fathers’ Network, Seattle, Washington, USA; Arthritis Research Center, Vancouver, British Columbia, Canada; Tools2use.eu, Bussum, The Netherlands; and the Department of Rheumatology, Cardiff University, Cardiff, UK. The OMERACT RA Flare working group received financial and/or logistical and data support from Novartis, Amgen Canada, UCB, and Pfizer. V. Bykerk, principal investigator of the CATCH cohort, has received research grants from, and/or served as a member of advisory boards for, Abbott Laboratories, Amgen, Antares, Astellas, Boehringer Ingelheim, Bristol Meyers Squibb, Janssen Biotech, Pfizer, Merck, Roche, Genentech, and UCB. She is funded by the Cedar Hill Foundation. E. Lie has served on advisory boards for and/or received consultancy/speaker honoraria from Pfizer, Roche, Bristol-Myers Squibb, and Abbvie. R. Alten has received research grants and served as a member of advisory boards and speaker bureaus of Abbott Laboratories, Bristol-Myers Squibb, Chugai Pharma, Horizon, GSK, MSD, Novartis, Pfizer, Roche, Schering Plough, and UCB. C.O. Bingham III has received research grants and/or served as a consultant to Abbott, Amgen, BMS, Celgene, Genentech/Roche, Janssen/Johnson and Johnson/Centocor, Pfizer, and UCB. Work reported in this publication has been supported by the Ira Fine Discovery Fund, the Sibley Hospital Memorial Fund, and the Johns Hopkins Arthritis Center Discovery Fund. S. Bartlett has received consultancy/speaker honoraria from Amgen, Pfizer, Roche, UCB, Biogen, and Abbott; A. Boonen received educational grants from Abbott, MSD, and Amgen and speakers’ honoraria from UCB, Abbott, and Pfizer. R. Christensen has received grant support and/or provided expert advice and/or presentations for Abbott/AbbVie, Axellus, Bayer HealthCare Pharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Cambridge Weight Plan, Ipsen, Laboratoires Expanscience, MSD, Mundipharma, Norpharma, Pfizer, Roche, and Wyeth. L. March is Chair of the Australian Biologics Registry, which receives unrestricted educational grants from Abbott Australasia, Pfizer Australia, Bristol Myers Squibb Australia, and Janssen-Cilag Australasia. A-M. Orbai is supported by the US National Institutes of Health T32-AR48522 and was supported to attend OMERACT 11 by the American College of Rheumatology and the Johns Hopkins Arthritis Center Discovery Fund. D. Furst has received research grants, and served as member of advisory boards and consultancy from Abbott, Actelion, Amgen, BMS, Biogen Idec, Janssen, Gilead, GSK, Novartis, Pfizer, Roche/Genentech, and UCB. He has also a member of the speaker bureau of Abbott, Actelion, and UCB. T. Woodworth is a former employee of Pfizer, Novartis, and Roche/Genentech. E. Choy has received research grants and served as member of advisory boards and speaker bureaus of Abbott Laboratories, Allergan, AstraZeneca, Boehringer Ingelheim, Chelsea Therapeutics, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Ferring Pharmaceutical, GSK, Jazz Pharmaceuticals, MedImmune, Merrimack Pharmaceutical, MSD, Novartis, Pfizer, Pierre Fabre Medicament, Roche, Schering Plough, Synovate, and UCB. V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery; E. Lie, MD, Department of Rheumatology, Diakonhjemmet Hospital; S.J. Bartlett, PhD, Johns Hopkins University, McGill University; R. Alten, MD, Schlosspark Klinik, Charité University Medicine; A. Boonen, MD, PhD, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute; R. Christensen, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital; D.E. Furst, MD, David Geffen School of Medicine, University of California at Los Angeles; S. Hewlett, PhD, RN, University of the West of England, Bristol, UK; A.L. Leong, Healthy Motivation, Bone and Joint Decade; A. Lyddiatt, Musculoskeletal Group, Cochrane Collaboration; L. March, MD, PhD, University of Sydney Department of Rheumatology, Royal North Shore Hospital; J.E. May, National Fathers’ Network; P. Montie, Arthritis Research Center; A-M. Orbai, MD, Johns Hopkins University; C. Pohl, MD, Schlosspark Klinik; M. Scholte Voshaar, Tools2use.eu; T. Woodworth, David Geffen School of Medicine, University of California at Los Angeles; C.O. Bingham III, MD, Johns Hopkins University; and E.H. Choy, MD, FRCP, Department of Rheumatology, Cardiff University. Address correspondence to Dr. Bykerk, Department of Rheumatology, Hospital for Special Surgery, 535 East 70th St., New York, New York 07030, USA. E-mail: bykerkv@hss.edu
Clifton O. Bingham III
From the Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Johns Hopkins University, Baltimore, Maryland, USA; McGill University, Montreal, Quebec, Canada; Schlosspark Klinik, Charité University Medicine, Berlin, Germany; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht, The Netherlands; Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark; David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA; University of the West of England, Bristol, UK; Healthy Motivation, Bone and Joint Decade, Santa Barbara, California, USA; Musculoskeletal Group, Cochrane Collaboration; University of Sydney Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; National Fathers’ Network, Seattle, Washington, USA; Arthritis Research Center, Vancouver, British Columbia, Canada; Tools2use.eu, Bussum, The Netherlands; and the Department of Rheumatology, Cardiff University, Cardiff, UK. The OMERACT RA Flare working group received financial and/or logistical and data support from Novartis, Amgen Canada, UCB, and Pfizer. V. Bykerk, principal investigator of the CATCH cohort, has received research grants from, and/or served as a member of advisory boards for, Abbott Laboratories, Amgen, Antares, Astellas, Boehringer Ingelheim, Bristol Meyers Squibb, Janssen Biotech, Pfizer, Merck, Roche, Genentech, and UCB. She is funded by the Cedar Hill Foundation. E. Lie has served on advisory boards for and/or received consultancy/speaker honoraria from Pfizer, Roche, Bristol-Myers Squibb, and Abbvie. R. Alten has received research grants and served as a member of advisory boards and speaker bureaus of Abbott Laboratories, Bristol-Myers Squibb, Chugai Pharma, Horizon, GSK, MSD, Novartis, Pfizer, Roche, Schering Plough, and UCB. C.O. Bingham III has received research grants and/or served as a consultant to Abbott, Amgen, BMS, Celgene, Genentech/Roche, Janssen/Johnson and Johnson/Centocor, Pfizer, and UCB. Work reported in this publication has been supported by the Ira Fine Discovery Fund, the Sibley Hospital Memorial Fund, and the Johns Hopkins Arthritis Center Discovery Fund. S. Bartlett has received consultancy/speaker honoraria from Amgen, Pfizer, Roche, UCB, Biogen, and Abbott; A. Boonen received educational grants from Abbott, MSD, and Amgen and speakers’ honoraria from UCB, Abbott, and Pfizer. R. Christensen has received grant support and/or provided expert advice and/or presentations for Abbott/AbbVie, Axellus, Bayer HealthCare Pharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Cambridge Weight Plan, Ipsen, Laboratoires Expanscience, MSD, Mundipharma, Norpharma, Pfizer, Roche, and Wyeth. L. March is Chair of the Australian Biologics Registry, which receives unrestricted educational grants from Abbott Australasia, Pfizer Australia, Bristol Myers Squibb Australia, and Janssen-Cilag Australasia. A-M. Orbai is supported by the US National Institutes of Health T32-AR48522 and was supported to attend OMERACT 11 by the American College of Rheumatology and the Johns Hopkins Arthritis Center Discovery Fund. D. Furst has received research grants, and served as member of advisory boards and consultancy from Abbott, Actelion, Amgen, BMS, Biogen Idec, Janssen, Gilead, GSK, Novartis, Pfizer, Roche/Genentech, and UCB. He has also a member of the speaker bureau of Abbott, Actelion, and UCB. T. Woodworth is a former employee of Pfizer, Novartis, and Roche/Genentech. E. Choy has received research grants and served as member of advisory boards and speaker bureaus of Abbott Laboratories, Allergan, AstraZeneca, Boehringer Ingelheim, Chelsea Therapeutics, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Ferring Pharmaceutical, GSK, Jazz Pharmaceuticals, MedImmune, Merrimack Pharmaceutical, MSD, Novartis, Pfizer, Pierre Fabre Medicament, Roche, Schering Plough, Synovate, and UCB. V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery; E. Lie, MD, Department of Rheumatology, Diakonhjemmet Hospital; S.J. Bartlett, PhD, Johns Hopkins University, McGill University; R. Alten, MD, Schlosspark Klinik, Charité University Medicine; A. Boonen, MD, PhD, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute; R. Christensen, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital; D.E. Furst, MD, David Geffen School of Medicine, University of California at Los Angeles; S. Hewlett, PhD, RN, University of the West of England, Bristol, UK; A.L. Leong, Healthy Motivation, Bone and Joint Decade; A. Lyddiatt, Musculoskeletal Group, Cochrane Collaboration; L. March, MD, PhD, University of Sydney Department of Rheumatology, Royal North Shore Hospital; J.E. May, National Fathers’ Network; P. Montie, Arthritis Research Center; A-M. Orbai, MD, Johns Hopkins University; C. Pohl, MD, Schlosspark Klinik; M. Scholte Voshaar, Tools2use.eu; T. Woodworth, David Geffen School of Medicine, University of California at Los Angeles; C.O. Bingham III, MD, Johns Hopkins University; and E.H. Choy, MD, FRCP, Department of Rheumatology, Cardiff University. Address correspondence to Dr. Bykerk, Department of Rheumatology, Hospital for Special Surgery, 535 East 70th St., New York, New York 07030, USA. E-mail: bykerkv@hss.edu
Ernest H. Choy
From the Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Johns Hopkins University, Baltimore, Maryland, USA; McGill University, Montreal, Quebec, Canada; Schlosspark Klinik, Charité University Medicine, Berlin, Germany; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht, The Netherlands; Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark; David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA; University of the West of England, Bristol, UK; Healthy Motivation, Bone and Joint Decade, Santa Barbara, California, USA; Musculoskeletal Group, Cochrane Collaboration; University of Sydney Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; National Fathers’ Network, Seattle, Washington, USA; Arthritis Research Center, Vancouver, British Columbia, Canada; Tools2use.eu, Bussum, The Netherlands; and the Department of Rheumatology, Cardiff University, Cardiff, UK. The OMERACT RA Flare working group received financial and/or logistical and data support from Novartis, Amgen Canada, UCB, and Pfizer. V. Bykerk, principal investigator of the CATCH cohort, has received research grants from, and/or served as a member of advisory boards for, Abbott Laboratories, Amgen, Antares, Astellas, Boehringer Ingelheim, Bristol Meyers Squibb, Janssen Biotech, Pfizer, Merck, Roche, Genentech, and UCB. She is funded by the Cedar Hill Foundation. E. Lie has served on advisory boards for and/or received consultancy/speaker honoraria from Pfizer, Roche, Bristol-Myers Squibb, and Abbvie. R. Alten has received research grants and served as a member of advisory boards and speaker bureaus of Abbott Laboratories, Bristol-Myers Squibb, Chugai Pharma, Horizon, GSK, MSD, Novartis, Pfizer, Roche, Schering Plough, and UCB. C.O. Bingham III has received research grants and/or served as a consultant to Abbott, Amgen, BMS, Celgene, Genentech/Roche, Janssen/Johnson and Johnson/Centocor, Pfizer, and UCB. Work reported in this publication has been supported by the Ira Fine Discovery Fund, the Sibley Hospital Memorial Fund, and the Johns Hopkins Arthritis Center Discovery Fund. S. Bartlett has received consultancy/speaker honoraria from Amgen, Pfizer, Roche, UCB, Biogen, and Abbott; A. Boonen received educational grants from Abbott, MSD, and Amgen and speakers’ honoraria from UCB, Abbott, and Pfizer. R. Christensen has received grant support and/or provided expert advice and/or presentations for Abbott/AbbVie, Axellus, Bayer HealthCare Pharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Cambridge Weight Plan, Ipsen, Laboratoires Expanscience, MSD, Mundipharma, Norpharma, Pfizer, Roche, and Wyeth. L. March is Chair of the Australian Biologics Registry, which receives unrestricted educational grants from Abbott Australasia, Pfizer Australia, Bristol Myers Squibb Australia, and Janssen-Cilag Australasia. A-M. Orbai is supported by the US National Institutes of Health T32-AR48522 and was supported to attend OMERACT 11 by the American College of Rheumatology and the Johns Hopkins Arthritis Center Discovery Fund. D. Furst has received research grants, and served as member of advisory boards and consultancy from Abbott, Actelion, Amgen, BMS, Biogen Idec, Janssen, Gilead, GSK, Novartis, Pfizer, Roche/Genentech, and UCB. He has also a member of the speaker bureau of Abbott, Actelion, and UCB. T. Woodworth is a former employee of Pfizer, Novartis, and Roche/Genentech. E. Choy has received research grants and served as member of advisory boards and speaker bureaus of Abbott Laboratories, Allergan, AstraZeneca, Boehringer Ingelheim, Chelsea Therapeutics, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Ferring Pharmaceutical, GSK, Jazz Pharmaceuticals, MedImmune, Merrimack Pharmaceutical, MSD, Novartis, Pfizer, Pierre Fabre Medicament, Roche, Schering Plough, Synovate, and UCB. V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery; E. Lie, MD, Department of Rheumatology, Diakonhjemmet Hospital; S.J. Bartlett, PhD, Johns Hopkins University, McGill University; R. Alten, MD, Schlosspark Klinik, Charité University Medicine; A. Boonen, MD, PhD, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute; R. Christensen, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital; D.E. Furst, MD, David Geffen School of Medicine, University of California at Los Angeles; S. Hewlett, PhD, RN, University of the West of England, Bristol, UK; A.L. Leong, Healthy Motivation, Bone and Joint Decade; A. Lyddiatt, Musculoskeletal Group, Cochrane Collaboration; L. March, MD, PhD, University of Sydney Department of Rheumatology, Royal North Shore Hospital; J.E. May, National Fathers’ Network; P. Montie, Arthritis Research Center; A-M. Orbai, MD, Johns Hopkins University; C. Pohl, MD, Schlosspark Klinik; M. Scholte Voshaar, Tools2use.eu; T. Woodworth, David Geffen School of Medicine, University of California at Los Angeles; C.O. Bingham III, MD, Johns Hopkins University; and E.H. Choy, MD, FRCP, Department of Rheumatology, Cardiff University. Address correspondence to Dr. Bykerk, Department of Rheumatology, Hospital for Special Surgery, 535 East 70th St., New York, New York 07030, USA. E-mail: bykerkv@hss.edu
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Establishing a Core Domain Set to Measure Rheumatoid Arthritis Flares: Report of the OMERACT 11 RA Flare Workshop
Vivian P. Bykerk, Elisabeth Lie, Susan J. Bartlett, Rieke Alten, Annelies Boonen, Robin Christensen, Daniel E. Furst, Sarah Hewlett, Amye L. Leong, Anne Lyddiatt, Lyn March, James E. May, Pam Montie, Ana-Maria Orbai, Christoph Pohl, Marieke Scholte Voshaar, Thasia Woodworth, Clifton O. Bingham , Ernest H. Choy
The Journal of Rheumatology Mar 2014, jrheum.131252; DOI: 10.3899/jrheum.131252
Establishing a Core Domain Set to Measure Rheumatoid Arthritis Flares: Report of the OMERACT 11 RA Flare Workshop
Vivian P. Bykerk, Elisabeth Lie, Susan J. Bartlett, Rieke Alten, Annelies Boonen, Robin Christensen, Daniel E. Furst, Sarah Hewlett, Amye L. Leong, Anne Lyddiatt, Lyn March, James E. May, Pam Montie, Ana-Maria Orbai, Christoph Pohl, Marieke Scholte Voshaar, Thasia Woodworth, Clifton O. Bingham , Ernest H. Choy
The Journal of Rheumatology Mar 2014, jrheum.131252; DOI: 10.3899/jrheum.131252